Treatment of acute promyelocytic leukemia (APL) with AS2O3 has unique favorable cure rates [79], and the major mechanism of action is through the degradation of PML-RARα, the driver of APL [80]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.